Manish R Patel
Overview
Explore the profile of Manish R Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
5572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hamilton E, Wang J, Oza A, Patel M, Ulahannan S, Bauer T, et al.
Mol Cancer Ther
. 2023 Jul;
22(10):1154-1165.
PMID: 37486983
AZD5153, a reversible, bivalent inhibitor of the bromodomain and extraterminal family protein BRD4, has preclinical activity in multiple tumors. This first-in-human, phase I study investigated AZD5153 alone or with olaparib...
22.
Mato A, Woyach J, Brown J, Ghia P, Patel K, Eyre T, et al.
N Engl J Med
. 2023 Jul;
389(1):33-44.
PMID: 37407001
Background: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options...
23.
Roschewski M, Patel M, Reagan P, Saba N, Collins G, Arkenau H, et al.
Clin Cancer Res
. 2023 Jun;
29(17):3301-3312.
PMID: 37364001
Purpose: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib has...
24.
Rondon L, Fu R, Patel M
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296902
Malignant pleural mesothelioma (MPM) is a malignancy associated with asbestos exposure and is typically categorized as an orphan disease. Recent developments in immunotherapy with anti-PD-1 and anti-CTLA-4 antibodies, specifically with...
25.
Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jun;
23(9):674-686.
PMID: 37290996
Background: The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are implicated in tumorigenesis; the pan-PIM kinase inhibitor, INCB053914, demonstrated antitumor activity in hematologic malignancy preclinical models. Patients...
26.
LoRusso P, Yamamoto N, Patel M, Laurie S, Bauer T, Geng J, et al.
Cancer Discov
. 2023 Jun;
13(8):1802-1813.
PMID: 37269344
Significance: We report phase Ia data indicating that the oral MDM2-p53 antagonist brigimadlin has a manageable safety profile and shows encouraging signs of efficacy in patients with solid tumors, particularly...
27.
Narkhede M, Bartlett N, Ibrahimi S, Popplewell L, Seto A, Bates J, et al.
EJHaem
. 2023 May;
4(2):370-380.
PMID: 37206279
Signal regulatory protein alpha (SIRPα) is the receptor for cluster of differentiation (CD)47, a potent "don't eat me" signal for macrophages. Disruption of CD47-SIRPα signaling in the presence of prophagocytic...
28.
Johnson M, Patel M, Aljumaily R, Jones S, Burris Iii H, Spigel D
Oncologist
. 2023 May;
28(7):640-e559.
PMID: 37129455
Background: This was an open-label, multicenter, single-arm phase Ib dose-escalation study of oral LCL161 administered in combination with oral topotecan in patients with relapsed/refractory small cell lung cancer (SCLC) and...
29.
Issa G, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al.
Nature
. 2023 Mar;
615(7954):920-924.
PMID: 36922593
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function. The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in...
30.
Johnson M, Strauss J, Patel M, Garon E, Eaton K, Neskorik T, et al.
Clin Lung Cancer
. 2023 Mar;
24(3):218-227.
PMID: 36890020
Background: Histone deacetylase (HDAC) inhibitors have potential to augment the effectiveness of immune checkpoint inhibitors and overcome treatment resistance. This dose-escalation/expansion study (NCT02805660) investigated mocetinostat (class I/IV HDAC inhibitor) plus...